As shown in Figure 4B, the α2-6 ST activity was found to be significantly upregulated in the CDC-resistant CLL cells treated (0.981±0.017) compared to the CDC-normal CLL cells (0.730±0.009, p<10-4) and to the B cell controls (0.721±0.011, p<10-4). Here, IGKV6-21 is linked to B-cell chronic lymphocytic leukemia.